Journal: Molecular cancer therapeutics
Article Title: Off Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
doi: 10.1158/1535-7163.MCT-13-0187
Figure Lengend Snippet: (A) Cell cycle analysis of SW1737, T2, TL3 thyroid cancer cell lines after treatment with increasing concentrations of Tivantinib and Crizotinib (0.1, 1.0, 10 μM, 24 hours). (B) Graphic display of G2/M data shown on Panel A. (C) Apoptosis measurement (% Annexin V positive cells) after these cells were treated with either Tivantinib or Crizotinib (0.1, 1.0, 10 μM, 24 hours). Results expressed as Mean ± SD. *: P < 0.05; **: P < 0.01.
Article Snippet: Compound c-MET inhibitors Tivantinib [ActiveBiochem (Maplewood, NJ)], Crizotinib and SU11274 [Selleck Chemical (Houston, TX)] were suspended in DMSO and stored until use in small aliquots at −20°C.
Techniques: Cell Cycle Assay